[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531528":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":54,"collaborators":57,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"High dose rate prostate brachytherapy",null,"Radiation. High dose rate prostate brachytherapy is delivered under anesthesia in 2 procedures, 1-2 weeks apart.\n\nHDR brachytherapy is also accomplished as an out-patient.",[13],"Radiation: High dose rate prostate brachytherapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.",[9],[20],"HDR brachytherapy",[22],{"name":23,"affiliation":24,"role":25},"Juanita M Crook, MD","Radiation Oncologist","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","250 712 3958","jcrook@bccancer.bc.ca",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"British Columbia Cancer Center for the Southern Interior","RECRUITING","Kelowna","British Columbia","V1Y 5L3","Canada","CA",{"type":41,"coordinates":42},"Point",[43,44],-119.48568,49.88307,{"lat":44,"lon":43},[47,49,52],{"name":48,"role":28,"phone":29,"phoneExt":10,"email":30},"Juanita Crook, MD",{"name":50,"role":51,"phone":10,"phoneExt":10,"email":10},"Hamid Raziee, MD","SUB_INVESTIGATOR",{"name":53,"role":51,"phone":10,"phoneExt":10,"email":10},"Bibi Naghibi Torbati, MD",{"type":25,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Juanita Crook","Professor of Radiation Oncology",[58,60,62],{"name":59,"class":6},"BC Cancer Foundation",{"name":61,"class":6},"University of British Columbia",{"name":63,"class":6},"Vancouver Prostate Centre","100531528","multi-omic-approach-to-study-hdr-brachytherapy-for-favorable-risk-and-low-tier-intermediate-risk-prostate-cancer-100531528",false,"NCT06200974","Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer","Multi-omic Approach to Study High Dose Rate (HDR) Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer","BrachyTRACKS","Inclusion Criteria:\n\n* Favorable risk and intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.\n* Clinical stage T1c-T2b, PSA \\\u003C 20, Gleason \\\u003C 8\n* ECOG 0-1\n* Low tier intermediate-risk prostate cancer is defined by: a single NCCN intermediate risk factor (either Gleason 7(3+4) and PSA \\\u003C 10 ng\u002Fml OR Gleason 6 and PSA 10-20 ng\u002Fml)\n* Extensive favorable-risk disease is defined as: clinical stage T1c-T2a, PSA \\\u003C 10, Gleason 6, ≥ 50% of biopsy cores containing cancer, PSA density \\> 0.2 ng\u002Fcc,\n* Selected intermediate risk patients not defined above\n\n  * T1c\u002FT2a\n  * PSA \\\u003C 10 and Gleason 4+3\n  * PSA \\> 10 (\\\u003C 20) and Gleason 3+4\n  * PSA 10-15 ng\u002Fml and Gleason 4+3 and \\\u003C 33% cores involved\n  * Max tumor length in any core 10 mm\n* No androgen deprivation therapy (ADT)\n* Signed study specific informed consent.\n\nExclusion Criteria:\n\n* Prior radical surgery for carcinoma of the prostate,\n* Prior pelvic radiation\n* Prior chemotherapy for prostate cancer,\n* Claustrophobic or unable to undergo MRI\n* Patients unsuitable for general anesthesia, on blood thinners which cannot be stopped for 24 hours, or who have contraindications to radiotherapy such as systemic sclerosis, or inflammatory bowel disease","ALL","18 Years",{"count":75,"type":76},100,"ESTIMATED","OBSERVATIONAL","This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.",[80],"Localized Prostate Carcinoma",[82,83,84,85,86,87],"Brachytherapy","TRACKS","High Dose Rate","Prostate cancer","favorable risk","intermediate risk","2026-01-29",{"date":90,"type":91},"2026-02-02","ACTUAL",{"date":93,"type":91},"2024-02-01",{"date":95,"type":76},"2038-02-01",{"name":5,"class":6},1]